Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis

• US 7,504,106 B2
• Filed: 03/14/2006
• Issued: 03/17/2009
• Est. Priority Date: 03/14/2006
• Status: Expired due to Fees

• Current Assignee: Boris Skurkovich, Ellen Millstein, Simon Skurkovich
• Original Assignee: Boris Skurkovich, Ellen Millstein, Simon Skurkovich
• Inventors: Millstein, Ellen, Skurkovich, Boris, Skurkovich, Simon
• Primary Examiner(s): Nickol; Gary B
• Assistant Examiner(s): Shafer; Shulamith H
• Application Number:
  US11/375,378
• Publication Number:
  US 20070218063A1
• Time in Patent Office: 1,099 Days
• Field of Search: None
• US Class Current: 424/158.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/245 IL-1
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/249 Interferons

Abstract

A method for treating patients with renal failure includes administering to them an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1 beta. Soluble cytokine receptors also can be employed. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof The composition can be included in a kit.

Claims

1. A method for treating renal failure in a patient suffering with advanced stage renal disease, the method comprising:

a. selecting a patient suffering from renal failure in advanced stage renal disease, wherein said renal failure is associated with elevated levels of one or more compounds selected from the group consisting of urea and creatinine and one or more cytokines selected from the group consisting of tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1 beta; and

b. administering to the patient antibodies to the one or more of said compounds associated with said renal failure and antibodies or soluble cytokine receptors to the one or more of said cytokines associated with said renal failure thereby reducing levels of the selected one or more compounds and the selected one or more cytokines in the patient.

2. The method of claim 1, wherein the antibodies to the one or more compounds and the antibodies or soluble cytokine receptors to the one or more cytokines are administered parenterally.

3. The method of claim 1, wherein the antibodies to the one or more compounds and the antibodies or soluble cytokine receptors to the one or more cytokines are administered at essentially the same time.

4. The method of claim 1, wherein the antibodies to the one or more compounds and the antibodies or soluble cytokine receptors to the one or more cytokines are administered at different times.

11. The method of claim 1, wherein the patient selected is a patient who receives dialysis.

5. A method for treating a patient suffering from renal failure in advanced stage renal disease, the patient exhibiting elevated levels of at least two compounds selected from the group consisting of urea, creatinine, tumor necrosis factor alpha, interferon gamma, and interleukin 6, the method comprising administering to the patient antibodies, or soluble cytokine receptors to the at least two compounds, wherein said antibodies or soluble cytokine receptors are administered in amounts effective to reduce levels of said two compounds.

6. The method of claim 5, wherein the amounts are administered in combination with a dialysis regimen.

7. The method of claim 5, wherein said antibodies are selected from the group consisting of monoclonal antibody, polyclonal antibody, chimeric antibody, camelid antibody, human antibody and humanized antibody.

8. The method of claim 5, wherein the antibodies, or soluble cytokine receptors are administered at essentially the same time.

9. The method of claim 5, wherein the antibodies, or soluble cytokine receptors are administered at different times.

10. A method for treating renal failure in a patient suffering from advanced stage renal disease exhibiting elevated levels of urea, creatinine or both, the method comprising administering to the patient an antibody to urea, creatinine or both, wherein the antibody is administered in an amount effective to reduce the patient'"'"'s levels of urea, creatinine or both.